The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Side effects of therapy of hepatitis C and their management
Open accessAbstract
Interferon and ribavirin combination therapy for chronic hepatitis C produces a number of well-described side effects that are dominated by fatigue, influenza-like symptoms, hematologic abnormalities, and neuropsychiatric symptoms. Combination therapy with pegylated interferons (peginterferon alfa-2a and alfa-2b) yields an adverse event profile similar to standard interferon, although the frequency of certain adverse events may vary by preparation. Premature withdrawal from therapy due to adverse events was required in 10% to 14% of participants in registration trials of these agents. Most adverse events were safely and effectively managed by dose reduction using predetermined criteria. The most common indications for dose reduction were hematologic abnormalities, such as anemia and neutropenia, with the latter more frequent in peginterferon treatment arms. Recent data suggest that maintaining adherence to a prescribed treatment regimen can enhance antiviral response. Strategies to maximize adherence are being developed and, in the future, may include early identification of and therapy for depression and the selective use of hematopoietic growth factors to ameliorate hematologic abnormalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Self-citationManns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
McHutchison, J. G., Manns, M., Patel, K., Poynard, T., Lindsay, K. L., Trepo, C., Dienstag, J., Lee, W. M., Mak, C., Garaud, J., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35950 · Cited by 969
Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data
Glue, P. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110973 · Cited by 504
Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease
Forton, D. M., Thomas, H. C., Murphy, C. A., Allsop, J. M., Foster, G. R., Main, J., Wesnes, K. A., & Taylor-Robinson, S. D. (2002) · Hepatology · doi:10.1053/jhep.2002.30688 · Cited by 450
De Franceschi, L., Fattovich, G., Turrini, F., Ayi, K., Brugnara, C., Manzato, F., Noventa, F., Stanzial, A. M., Solero, P., & Corrocher, R. (2000) · Hepatology · doi:10.1053/he.2000.5789 · Cited by 446
Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H., & Maes, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00014 · Cited by 437
Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression
Mace, S., & Taylor, D. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.5.917 · Cited by 315
Neuropsychological impairment in patients with chronic hepatitis C
Hilsabeck, R. C., Perry, W., & Hassanein, T. I. (2002) · Hepatology · doi:10.1053/jhep.2002.31257 · Cited by 288
Depression, fatigue, and functional disability in patients with chronic hepatitis C
Dwight, M. M., Kowdley, K. V., Russo, J. E., Ciechanowski, P. S., Larson, A. M., & Katon, W. J. (2000) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(00)00155-0 · Cited by 258
Fatigue in patients with chronic hepatitis C
Poynard, T., Cacoub, P., Ratziu, V., Myers, R. P., Dezailles, M. H., Mercadier, A., Ghillani, P., Charlotte, F., Piette, J. C., Moussalli, J., et al. (2002) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2002.00364.x · Cited by 247
Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.
McHutchison, J. G., & Poynard, T. (1999) · PubMed · Cited by 243
Hepatitis C, interferon alfa, and depression
Zdilar, D., Franco-Bronson, K., Buchler, N., Locala, J. A., & Younossi, Z. M. (2000) · Hepatology · doi:10.1053/jhep.2000.7880 · Cited by 215
Trask, P. C., Esper, P., Riba, M., & Redman, B. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2316 · Cited by 191
Implications of Interferon-Induced Tryptophan Catabolism in Cancer, Autoimmune Diseases and Aids
Brown, R. R., Ozaki, Y., Datta, S. P., Borden, E. C., Sondel, P. M., & Malone, D. G. (1991) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4684-5952-4_39 · Cited by 174
Paroxetine for the treatment of interferon‐α‐induced depression in chronic hepatitis C
Kraus, M. R., Schäfer, A., Faller, H., Csef, H., & Scheurlen, M. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01265.x · Cited by 170
Morikawa, O., Sakai, N., Obara, H., & Saito, N. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00187-3 · Cited by 160
Maddrey, W. C. (1999) · PubMed · Cited by 158
Hübel, K., Dale, D. C., & Liles, W. C. (2002) · The Journal of Infectious Diseases · doi:10.1086/340221 · Cited by 150
Leukopenia, Neutropenia, and Reduced Hemoglobin Levels in Healthy American Blacks
Reed, W. W. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400030063011 · Cited by 129
Retinopathy associated with high-dose interferon alfa-2b therapy
Hejny, C., Sternberg, P., Lawson, D. H., Greiner, K., & Aaberg, T. M. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00836-4 · Cited by 108
An Open-Label Trial of Citalopram for Major Depression in Patients With Hepatitis C
Gleason, O. C., Yates, W. R., Isbell, M. D., & Philipsen, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0304 · Cited by 100
Management of infection in cancer patients
Viscoli, C. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00461-0 · Cited by 94
Berghmans, T., Paesmans, M., Lafitte, J., Mascaux, C., Meert, A., Jacquy, C., Burniat, A., Steels, E., Vallot, F., & Jp, S. (2002) · Supportive Care in Cancer · doi:10.1007/s00520-001-0312-5 · Cited by 93
Singh, N., Gayowski, T., Wagener, M. M., & Marino, I. R. (1997) · Clinical Transplantation · doi:10.1111/j.1399-0012.1997.tb00842.x · Cited by 82
Neary, M. P., Cort, S., Bayliss, M. S., & Ware, J. E. (1999) · PubMed · Cited by 80
Leonard, J. P., & Link, B. K. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30149 · Cited by 74
Kraus, M. R., Schäfer, A., Csef, H., Faller, H., Mörk, H., & Scheurlen, M. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1011973823032 · Cited by 73
Neuropsychiatric Toxicity of Antiviral Treatment in Chronic Hepatitis C
Fontana, R. J. (2000) · Digestive Diseases · doi:10.1159/000051384 · Cited by 68
Depression in Korean Immigrants With Hepatitis B and Related Liver Diseases
Kunkel, E. J. S., Kim, J. S., Hann, H. W., Oyesanmi, O., Menefee, L. A., Field, H. L., Lartey, P. L., & Myers, R. E. (2000) · Psychosomatics · doi:10.1176/appi.psy.41.6.472 · Cited by 67
The evolution of the empirical management of fever and neutropenia in cancer patients
Viscoli, C. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/41.suppl_4.65 · Cited by 65
Adverse Effects of Interferon on the Cardiovascular System in Patients with Chronic Hepatitis C.
Teragawa, H., 本藤, 達., Amano, H., Hino, F., & Ohbayashi, M. (1996) · Japanese Heart Journal · doi:10.1536/ihj.37.905 · Cited by 62
Incidence of interferon alfa-induced depression in patients with chronic hepatitis C
Castéra, L., Zigante, F., Bastie, A., Buffet, C., Dhumeaux, D., & Hardy, P. (2002) · Hepatology · doi:10.1053/jhep.2002.32104 · Cited by 44
Treatment of Hepatitis C and Anemia in Human Immunodeficiency Virus–Infected Patients
Dieterich, D. T. (2002) · The Journal of Infectious Diseases · doi:10.1086/340199 · Cited by 35
Scalori, A., Apale, P., Panizzuti, F., Mascoli, N., Pioltelli, P. E., Pozzi, M., Redaelli, A. E., Roffi, L., & Mancia, G. (2000) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200012050-00005 · Cited by 34
Fukuda, A., Kobayashi, H., Teramura, K., Yoshimoto, S., & Ohsawa, N. (2000) · Cytokines Cellular & Molecular Therapy · doi:10.1080/mccm.6.3.149.154 · Cited by 26
Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies
Kasper, C. (2001) · Annals of Hematology · doi:10.1007/s002770100333 · Cited by 25
Moore, J. D., & Bona, J. R. (2001) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70333-3 · Cited by 25
Cited by
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.449 · Cited by 2,141
Diagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
EASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
Metadata
- Authors
- Fried, M. W.
- Venue
- Hepatology
- Published
- 2002-11
- Volume
- 36
- Issue
- 5 Suppl 1
- Pages
- s237-s244
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2072160870
- Cited by
- 727
- References
- 41
- FWCI
- 21.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.